NeuVasQ Biotechnologies Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$24.2M
- Investors
-
10
NeuVasQ Biotechnologies General Information
Description
Developer of pharmaceutical treatments designed to treat neurological disorders by repairing neurovascular function. The company's platform assists in restoring blood-brain barrier function in acute neurological disorders such as stroke and epilepsy, traumatic brain injury, and brain cancer, as well as neurodegenerative diseases like Alzheimer's, enabling doctors to improve patient lives in a wide range of neurological disorders.
Contact Information
Website
www.neuvasq.comCorporate Office
- Rue Auguste Piccard 48
- ULB Open Lab, Bâtiment Biopole
- 6041 Gosselies
- Belgium
Corporate Office
- Rue Auguste Piccard 48
- ULB Open Lab, Bâtiment Biopole
- 6041 Gosselies
- Belgium
NeuVasQ Biotechnologies Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC (Series A) | 22-Jun-2021 | $24.2M | Completed | Pre-Clinical Trials | ||
| 1. University Spin-Out | 05-Feb-2021 | Completed | Startup |
NeuVasQ Biotechnologies Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A |
NeuVasQ Biotechnologies Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
NeuVasQ Biotechnologies Patents
NeuVasQ Biotechnologies Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026220051-A1 | Composition for the treatement of seizure or epilepsy | Pending | 18-Apr-2025 | ||
| WO-2026219985-A1 | Bispecific antibodies binding to fzd4 and gpr124 and/or reck | Pending | 16-Apr-2025 | ||
| WO-2026219984-A1 | Bispecific antibodies binding to gpr124 and reck | Pending | 16-Apr-2025 | ||
| WO-2026219987-A1 | Trispecific antibodies binding to lrp5/6, grp124 and reck and modulating wnt7 | Pending | 16-Apr-2025 | ||
| WO-2026219989-A1 | Trispecific antibodies binding to lrp6, fzd4 and gpr124 and/or reck | Pending | 16-Apr-2025 | C07K16/28 |
NeuVasQ Biotechnologies Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
NeuVasQ Biotechnologies Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Carbon ( Belgium ) | Venture Capital | Minority | ||
| EEBIC | PE-Backed Company | Minority | ||
| Newton BioCapital | Venture Capital | Minority | ||
| ORSA FUND | Venture Capital | Minority | ||
| Angel (individual) | Minority |
NeuVasQ Biotechnologies FAQs
-
When was NeuVasQ Biotechnologies founded?
NeuVasQ Biotechnologies was founded in 2021.
-
Where is NeuVasQ Biotechnologies headquartered?
NeuVasQ Biotechnologies is headquartered in Gosselies, Belgium.
-
What is the size of NeuVasQ Biotechnologies?
NeuVasQ Biotechnologies has 10 total employees.
-
What industry is NeuVasQ Biotechnologies in?
NeuVasQ Biotechnologies’s primary industry is Drug Discovery.
-
Is NeuVasQ Biotechnologies a private or public company?
NeuVasQ Biotechnologies is a Private company.
-
What is the current valuation of NeuVasQ Biotechnologies?
The current valuation of NeuVasQ Biotechnologies is .
-
What is NeuVasQ Biotechnologies’s current revenue?
The current revenue for NeuVasQ Biotechnologies is .
-
How much funding has NeuVasQ Biotechnologies raised over time?
NeuVasQ Biotechnologies has raised $24.2M.
-
Who are NeuVasQ Biotechnologies’s investors?
Carbon ( Belgium ), EEBIC, Newton BioCapital, ORSA FUND, and are 5 of 10 investors who have invested in NeuVasQ Biotechnologies.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
